Anthera Pharmaceuticals Company Profile (NASDAQ:ANTH)

About Anthera Pharmaceuticals

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANTH
  • CUSIP:
Key Metrics:
  • Previous Close: $3.14
  • 50 Day Moving Average: $3.09
  • 200 Day Moving Average: $3.41
  • 52-Week Range: $41,427,000.00 - $2.28
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.38
  • P/E Growth: 0.00
  • Market Cap: $132.15M
  • Outstanding Shares: 41,427,000
  • Beta: 1.8
Profitability:
  • Net Margins: -1,273.45%
  • Return on Equity: -131.24%
  • Return on Assets: -102.15%
Debt:
  • Current Ratio: 2.94%
  • Quick Ratio: 2.94%
Additional Links:
Companies Related to Anthera Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Anthera Pharmaceuticals (NASDAQ:ANTH) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $10.00 (213.48% upside)

Analysts' Ratings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Show:
DateFirmActionRatingPrice TargetDetails
8/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
7/8/2016HC WainwrightInitiated CoverageBuy$10.00View Rating Details
6/20/2016FBR & CoReiterated RatingHoldView Rating Details
3/11/2016Piper Jaffray Cos.Lower Price TargetOverweight$14.00 -> $10.00View Rating Details
2/19/2016Citigroup Inc.Lower Price Target$15.00 -> $11.00View Rating Details
9/8/2015SunTrust Banks Inc.Initiated CoverageBuy$14.00View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016        
8/9/2016Q2($0.31)($0.35)ViewN/AView Earnings Details
5/9/2016Q1($0.28)($0.29)ViewN/AView Earnings Details
3/10/2016Q4($0.27)($0.18)$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($0.25)($0.29)ViewN/AView Earnings Details
8/10/2015Q2($0.28)($0.25)ViewN/AView Earnings Details
5/11/2015Q115($0.31)($0.28)ViewN/AView Earnings Details
3/16/2015($0.33)($0.32)ViewN/AView Earnings Details
11/14/2014($0.39)($0.31)ViewN/AView Earnings Details
7/28/2014($0.49)($0.34)ViewN/AView Earnings Details
5/13/2014Q114($0.46)($0.39)ViewN/AView Earnings Details
3/12/2014($0.47)($0.48)ViewN/AView Earnings Details
3/26/2013Q412($0.15)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)
Current Year EPS Consensus Estimate: $-1.33 EPS
Next Year EPS Consensus Estimate: $-1.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.30)($0.30)($0.30)
Q2 20162($0.30)($0.29)($0.30)
Q3 20162($0.35)($0.33)($0.34)
Q4 20162($0.32)($0.31)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anthera Pharmaceuticals (NASDAQ:ANTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Insider Ownership Percentage: 5.13%
Institutional Ownership Percentage: 55.24%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.00View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.00View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.75View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Anthera Pharmaceuticals (NASDAQ:ANTH)
DateHeadline
News IconPenny Stock Investors Keen on Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - September 21 at 4:24 PM
News IconResearch Reports Initiation on Biotech Stocks -- Agenus, Nektar Therapeutics, GlobeImmune and Anthera Pharma (NASDAQ:ANTH)
www.kswo.com - September 21 at 9:14 AM
4-traders.com logoAnthera Pharmaceuticals : Research Reports Initiation on Biotech Stocks -- Agenus, Nektar Therapeutics, GlobeImmune and Anthera Pharma (NASDAQ:ANTH)
www.4-traders.com - September 21 at 9:14 AM
insidermonkey.com logoAnthera Pharmaceuticals Inc (ANTH): Biotechnology Value Fund Reports 9.99% Stake (NASDAQ:ANTH)
www.insidermonkey.com - September 21 at 9:14 AM
insidermonkey.com logoAnthera Pharmaceuticals Inc (ANTH): Biotechnology Value Fund Reports 9.99% Stake - Insider Monkey (blog) (NASDAQ:ANTH)
www.insidermonkey.com - September 19 at 4:27 PM
News IconWhat is the Sell-side Saying About Anthera Pharmaceuticals, Inc ... - Frisco Fastball (NASDAQ:ANTH)
friscofastball.com - September 19 at 8:14 AM
News IconWhy Biotechnology Value Fund L P Reported Big Anthera Pharmaceuticals Inc Position? - Post News (NASDAQ:ANTH)
www.kentuckypostnews.com - September 17 at 8:19 AM
4-traders.com logoANTHERA PHARMACEUTICALS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) (NASDAQ:ANTH)
www.4-traders.com - September 15 at 8:40 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fina (NASDAQ:ANTH)
biz.yahoo.com - September 15 at 8:40 PM
News IconWere Analysts Bullish Anthera Pharmaceuticals Inc (NASDAQ:ANTH ... - Frisco Fastball (NASDAQ:ANTH)
friscofastball.com - September 14 at 8:05 AM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to Articles of (NASDAQ:ANTH)
biz.yahoo.com - September 13 at 8:21 AM
News IconWhat is the Sell-side Saying About Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)? - Frisco Fastball (NASDAQ:ANTH)
friscofastball.com - September 9 at 3:28 PM
News IconShares Higher in Today's Session: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Post News (NASDAQ:ANTH)
www.kentuckypostnews.com - September 9 at 8:18 AM
News IconPlacing Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Shares Under the Microscope - Post News (NASDAQ:ANTH)
www.kentuckypostnews.com - September 9 at 8:18 AM
News IconFocusing the Spotlight on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - September 8 at 3:29 PM
globenewswire.com logoAnthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million Registered Direct ... - GlobeNewswire (press release) (NASDAQ:ANTH)
globenewswire.com - September 8 at 11:04 AM
publicnow.com logoAnthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million Registered Direct Offering to Biotechnology Value Fund and Rock Springs Capital (NASDAQ:ANTH)
www.publicnow.com - September 8 at 11:04 AM
News IconNarrowing the Lens on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - September 7 at 12:28 PM
News IconOTC Investors Supremely Interested in Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - September 6 at 3:29 PM
News IconA Second Look at Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - September 2 at 3:32 PM
News IconZeroing Our Focus on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - August 30 at 3:29 PM
News IconOTC Investors Keen on Shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Duncan Research (NASDAQ:ANTH)
www.duncanindependent.com - August 27 at 8:19 AM
investornewswire.com logoWill Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Hit $14 Price Target? - Investor Newswire (NASDAQ:ANTH)
www.investornewswire.com - August 20 at 3:33 PM
News IconAnthera Pharmaceuticals, Inc.'s (ANTH): Running Mover to Focus - Hot Stocks Point (NASDAQ:ANTH)
www.hotstockspoint.com - August 18 at 3:38 PM
finance.yahoo.com logoANTHERA PHARMACEUTICALS INC Financials (NASDAQ:ANTH)
finance.yahoo.com - August 18 at 3:38 PM
marketwatch.com logoAnthera Pharma stock rises 7% on safety review board's go-ahead for late-stage drug trial - MarketWatch (NASDAQ:ANTH)
www.marketwatch.com - August 17 at 8:59 PM
News IconStock Gapping Up Pre-Market: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Post News (NASDAQ:ANTH)
www.kentuckypostnews.com - August 17 at 11:43 AM
News IconStock's Traders Recap- Anthera Pharmaceuticals, Inc.'s (ANTH) - Hot Stocks Point (NASDAQ:ANTH)
www.hotstockspoint.com - August 17 at 11:43 AM
finance.yahoo.com logoAnthera Pharmaceuticals (ANTH) Jumps: Stock Rises 7.9% (NASDAQ:ANTH)
finance.yahoo.com - August 17 at 11:43 AM
4-traders.com logoANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NASDAQ:ANTH)
www.4-traders.com - August 16 at 8:47 PM
reuters.com logoBRIEF-Anthera Pharmaceuticals names William Shanahan Jr. as chief medical officer (NASDAQ:ANTH)
www.reuters.com - August 16 at 8:47 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E (NASDAQ:ANTH)
biz.yahoo.com - August 16 at 8:47 PM
publicnow.com logoAnthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer (NASDAQ:ANTH)
www.publicnow.com - August 16 at 8:47 PM
News IconStock Moving Up in Session: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) - Post News (NASDAQ:ANTH)
www.kentuckypostnews.com - August 16 at 3:32 PM
reuters.com logoBRIEF-Anthera announces positive DSMB review in phase 3 solution study of Sollpura (NASDAQ:ANTH)
www.reuters.com - August 16 at 12:08 PM
finance.yahoo.com logoAnthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™ (NASDAQ:ANTH)
finance.yahoo.com - August 16 at 12:08 PM
marketwatch.com logoAnthera Pharma stock rises 7% on safety review board's go-ahead for late-stage drug trial (NASDAQ:ANTH)
www.marketwatch.com - August 16 at 12:08 PM
247wallst.com logoTuesday’s Top Health Care Movers (NASDAQ:ANTH)
247wallst.com - August 16 at 12:08 PM
reuters.com logoBRIEF-Anthera Pharmaceuticals Q2 loss per share $0.35 (NASDAQ:ANTH)
www.reuters.com - August 10 at 10:17 AM
twst.com logoAnthera Pharmaceuticals Inc.: Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results (NASDAQ:ANTH)
www.twst.com - August 10 at 10:17 AM
reuters.com logoBRIEF-Anthera Pharmaceuticals Q2 loss per share $0.35 - Reuters (NASDAQ:ANTH)
www.reuters.com - August 9 at 4:35 PM
nasdaq.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results - Nasdaq (NASDAQ:ANTH)
www.nasdaq.com - August 9 at 4:35 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ANTH)
biz.yahoo.com - August 9 at 4:35 PM
biz.yahoo.com logoANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (NASDAQ:ANTH)
biz.yahoo.com - August 9 at 4:35 PM
twst.com logoAnthera Pharmaceuticals Inc.: Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter ... - The Wall Street Transcript (NASDAQ:ANTH)
www.twst.com - August 9 at 12:16 PM
sg.finance.yahoo.com logoAnthera reports 2Q loss (NASDAQ:ANTH)
sg.finance.yahoo.com - August 9 at 12:16 PM
publicnow.com logoAnthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results (NASDAQ:ANTH)
www.publicnow.com - August 9 at 12:16 PM
tradecalls.org logoAnthera Pharmaceuticals (ANTH) Shares are Up 2.92% - Trade Calls (NASDAQ:ANTH)
www.tradecalls.org - August 8 at 3:33 PM
businesswire.com logoInspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director (NASDAQ:ANTH)
www.businesswire.com - August 4 at 9:16 PM
globenewswire.com logoAnthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod - GlobeNewswire (press release) (NASDAQ:ANTH)
globenewswire.com - August 4 at 12:01 PM

Social

Anthera Pharmaceuticals (NASDAQ:ANTH) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff